Skip to main content
Clinical Trials/NCT00985036
NCT00985036WithdrawnNot Applicable

Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?

Marquette General Health System1 site in 1 countryStarted: September 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Locations
1
Primary Endpoint
Determine if VEGF levels correlate with tumor progression or recurrence

Study Overview

Brief Summary

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

  1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
  2. Is the VEGF level an indicator of the response to treatment?
  3. Does the VEGF level correlate with tumor histology and behavior?
  4. Is there a relationship between VEGF level and outcome?

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • any patient presenting with glioma or meningioma

Exclusion Criteria

  • a different type of brain tumor

Outcomes

Primary Outcomes

Determine if VEGF levels correlate with tumor progression or recurrence

Time Frame: every one to three months

Secondary Outcomes

  • Determine if the VEGF level is an indicator of the response to treatment.(Every one to three months)
  • Determine if the VEGF level correlates with tumor histology and behavior.(Every one to three months)
  • Determine if there is a relationship between VEGF level and outcome.(Every one to three months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Richard A. Rovin, MD FACS

Neurosurgeon

Marquette General Health System

Study Sites (1)

Loading locations...

Similar Trials